Cimerli

AssetAlso called FYB201

Neutralizes VEGF-A to inhibit abnormal blood vessel growth and vascular leakage.

Stage
Approved
Modality
Antibody
Target
Not known
6
Indications
0
Trials
1
Developer

Approved by the FDA on Aug 2, 2022 (BLA761165). FDA

Indications

6
  • Diabetic macular edema

    Approved, FDA

  • Diabetic retinopathy

    Approved, FDA

  • Macular edema

    Approved, FDA

3 more

In the full profile

  • Owner and partners1
  • Competitors12

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets